<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03793322</url>
  </required_header>
  <id_info>
    <org_study_id>201803</org_study_id>
    <nct_id>NCT03793322</nct_id>
  </id_info>
  <brief_title>The Application of Indocyanine-Green(ICG) Fluorescence Imaging in Hepatocellular Carcinoma</brief_title>
  <official_title>The Application of Indocyanine-Green(ICG) Fluorescence Imaging in Hepatocellular Carcinoma</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Zhujiang Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Zhujiang Hospital</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study aims to evaluate the feasibility of indocyanine green (ICG)-based fluorescence
      imaging in the detection of liver tumors. By correlating the ICG fluorescence patterns with
      pathologically confirmed tumors , it would be possible to use fluorescence navigation system
      in helping promoting oncology treatment.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">January 1, 2017</start_date>
  <completion_date type="Anticipated">December 31, 2020</completion_date>
  <primary_completion_date type="Anticipated">January 1, 2020</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Diagnostic</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>The accuracy of detecting small liver tumor by ICG fluorescence.</measure>
    <time_frame>3 Days</time_frame>
    <description>The tumor which aggregate ICG fluorescence will be resected and dignosed by pathology. The accuracy of detecting small liver tumor by ICG fluorescence will be evaluated.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>The accuracy of positive margins of resection detected by ICG fluorescence.</measure>
    <time_frame>3 Days</time_frame>
    <description>The surgery margins will be detected by ICG fluorescence. If there is fluorescence aggregating, we consider the presence of residual tumor in the margin and proven by histological examination.</description>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">100</enrollment>
  <condition>Hepatocellular Carcinoma</condition>
  <arm_group>
    <arm_group_label>Indocyanine-Green(ICG) injection group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Indocyanine-Green(ICG)</intervention_name>
    <description>ICG was administered intravenously 24 hours before the operation , or directly into the portal vein branches supplying the tumor-bearing hepatic segment, after puncturing of the target segments under intraoperative ultrasonography guidance.</description>
    <arm_group_label>Indocyanine-Green(ICG) injection group</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  18 years≤ Age ≤70 years

          -  Compling with the diagnosis criteria of hepatic carcinoma.

          -  Primary hepatic carcinoma without intrahepatic or extrahepatic extensive cancer
             metastasis, the metastatic hepatic carcinoma whose primary focal has been controlled.

          -  Preoperative liver function is Child - Pugh grade A or B.

          -  The patients are volunteered for the study.

        Exclusion Criteria:

          -  Patients with mental illness.

          -  Patients can't tolerate the operation owe to a variety of basic diseases (such as
             severe cardiopulmonary insufficiency, renal insufficiency, cachexia and blood system
             diseases, etc.

          -  The patients refused to take part in the study.

          -  There are other co-existed malignant tumors.

          -  Benign liver diseases.

          -  Indocyanine green allergy
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Chihua Fang</last_name>
    <role>Principal Investigator</role>
    <affiliation>China, Guangdong Zhujiang Hospital of The Southern Medical University</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Chihua Fang, MD; PHD</last_name>
    <phone>+8613609700805</phone>
    <email>fangch_dr@126.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Zhujiang Hospital of Southern Medical University</name>
      <address>
        <city>Guangzhou</city>
        <state>Guangdong</state>
        <zip>510282</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Chihua Fang, MD</last_name>
      <phone>(+86)2062782568</phone>
      <email>s_mountain@126.com</email>
    </contact>
    <contact_backup>
      <last_name>Qingshan Chen, MM</last_name>
      <phone>(+86)2062782568</phone>
      <email>s_mountain@126.com</email>
    </contact_backup>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>January 2017</verification_date>
  <study_first_submitted>January 2, 2019</study_first_submitted>
  <study_first_submitted_qc>January 2, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">January 4, 2019</study_first_posted>
  <last_update_submitted>January 2, 2019</last_update_submitted>
  <last_update_submitted_qc>January 2, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">January 4, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Hepatocellular Carcinoma</keyword>
  <keyword>Indocyanine-Green(ICG)</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Carcinoma</mesh_term>
    <mesh_term>Carcinoma, Hepatocellular</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

